Stocktoria
Gossamer Bio, Inc. GOSS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-02-08
Chart by TradingView
0/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $48.5M | $114.7M | $0 | $0 | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
| Shareholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M |
| Ratios | |||||
| Operating margin | -352.2% | -52.2% | — | — | — |
| Net margin | -351.5% | -49.3% | — | — | — |
| FCF margin | -353.5% | -3.0% | — | — | — |
| Return on assets | -98.9% | -17.9% | -57.6% | -84.2% | -68.1% |
| Return on equity | 138.8% | -191.7% | -286.5% | -1899.3% | -192.7% |
| Debt / equity | — | 0.00× | 0.01× | 0.99× | 0.24× |
| Current ratio | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 |
| Revenue growth | -57.7% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,217,868 | $400,070 |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001728117 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.